Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.35 |
| ▸ | AHCY | P23526 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | OGG1 | O15527 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191358 | 0.86 | L3MBTL1 (0.49) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL30571417 | 0.85 | POLB (0.45) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16719281 | 0.85 | POLB (0.45) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL191131 | 0.85 | POLB (0.45) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL191130 | 0.85 | POLB (0.45) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16719299 | 0.84 | POLB (0.44) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16719301 | 0.84 | POLB (0.44) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16719300 | 0.83 | L3MBTL1 (0.36) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL21485111 | 0.83 | L3MBTL1 (0.36) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| Potassium Ion SCHEMBL191177 | 0.83 | L3MBTL1 (0.36) | L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328091-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8895566-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2250155-B1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130085135-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-8329709-B2 | 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| EP-2250155-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009089462-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | L3MBTL1 2493/4885CYP3A4 3559/4885CYP1A2 3104/4885 |
| US-20130085135-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | L3MBTL1 2493/4885CYP3A4 3559/4885CYP1A2 3104/4885 |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | AKT3, PIK3CA, AKT2 | L3MBTL1 2607/4885CYP3A4 3693/4885CYP1A2 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.